MX2020009154A - Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer. - Google Patents

Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.

Info

Publication number
MX2020009154A
MX2020009154A MX2020009154A MX2020009154A MX2020009154A MX 2020009154 A MX2020009154 A MX 2020009154A MX 2020009154 A MX2020009154 A MX 2020009154A MX 2020009154 A MX2020009154 A MX 2020009154A MX 2020009154 A MX2020009154 A MX 2020009154A
Authority
MX
Mexico
Prior art keywords
cancer
nuc
alaninyl
benzoxy
phenyl
Prior art date
Application number
MX2020009154A
Other languages
English (en)
Inventor
Hugh Griffith
Chris Mcguigan
Chris Pepper
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020009154(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by NuCana plc filed Critical NuCana plc
Publication of MX2020009154A publication Critical patent/MX2020009154A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La invención provee NUC-1031 (gemcitabina-[fenil-benzoxi-L-alanini l)]-fosfato), un derivado ProTide de gemcitabina, para usarse para hacer blanco en las células madre de cáncer; esta acción de hacer blanco en las células madre de cáncer se puede usar en la prevención o tratamiento del cáncer; la invención también provee NUC-1031 para usarse en el tratamiento de la recidiva de cáncer o cáncer refractario en un paciente humano; sin desear limitarse por hipótesis alguna, se cree que la capacidad de NUC-1031 para hacer blanco en las células madre de cáncer contribuye a su utilidad en el tratamiento de la recidiva de cáncer o cáncer refractario.
MX2020009154A 2015-05-14 2015-05-14 Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer. MX2020009154A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2015/051438 WO2016181093A1 (en) 2015-05-14 2015-05-14 Cancer treatments

Publications (1)

Publication Number Publication Date
MX2020009154A true MX2020009154A (es) 2022-03-08

Family

ID=53276184

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014544A MX2017014544A (es) 2015-05-14 2015-05-14 Tratamientos del cáncer.
MX2020009154A MX2020009154A (es) 2015-05-14 2015-05-14 Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017014544A MX2017014544A (es) 2015-05-14 2015-05-14 Tratamientos del cáncer.

Country Status (25)

Country Link
US (3) US20180289733A1 (es)
EP (2) EP3197456B2 (es)
JP (1) JP6761852B2 (es)
KR (1) KR20180021697A (es)
CN (2) CN115837028A (es)
AU (2) AU2015394135B2 (es)
BR (1) BR112017024461B1 (es)
CA (1) CA2985540C (es)
CY (1) CY1120516T1 (es)
DK (1) DK3197456T3 (es)
EA (1) EA201792509A1 (es)
ES (1) ES2668377T3 (es)
HR (1) HRP20180762T1 (es)
HU (1) HUE038541T2 (es)
IL (1) IL255591B (es)
LT (1) LT3197456T (es)
MX (2) MX2017014544A (es)
MY (1) MY192081A (es)
PH (1) PH12017502086A1 (es)
PL (1) PL3197456T3 (es)
PT (1) PT3197456T (es)
RS (1) RS57371B1 (es)
SI (1) SI3197456T1 (es)
TR (1) TR201806642T4 (es)
WO (1) WO2016181093A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
JP5978232B2 (ja) 2011-03-01 2016-08-24 ニューカナー、バイオメッド、リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ がん治療での使用のための５−フルオロ−２’−デオキシウリジンのホスホラミダート誘導体
HUE044605T2 (hu) 2012-11-16 2019-11-28 Univ College Cardiff Consultants Ltd RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke
WO2015198059A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Formulation comprising a gemcitabine-prodrug
MX2021001140A (es) 2014-06-25 2022-04-21 Nucana Biomed Ltd Profármacos de gemcitabina.
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
MX2020010375A (es) 2014-11-28 2022-07-19 NuCana plc Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer.
WO2017050889A1 (en) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
WO2017060661A1 (en) 2015-10-05 2017-04-13 Nucana Biomed Limited Combination therapy
AU2016367237B2 (en) 2015-12-11 2020-12-24 Laurus Labs Limited Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug NUC-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
ME03677B (me) * 2015-12-23 2020-10-20 NuCana plc Kombinovana terapija
KR102566461B1 (ko) * 2015-12-23 2023-08-14 뉴카나 피엘씨 조합 요법
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
US20210315878A1 (en) * 2018-10-12 2021-10-14 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reducing cancer stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CA2736563C (en) * 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
CN102144163A (zh) * 2008-04-10 2011-08-03 麻省理工学院 关于鉴定和使用靶向癌症干细胞的试剂的方法

Also Published As

Publication number Publication date
HRP20180762T1 (hr) 2018-08-24
BR112017024461A2 (pt) 2018-07-24
AU2021277614A1 (en) 2021-12-23
EP3197456B1 (en) 2018-04-04
AU2015394135A1 (en) 2017-12-14
IL255591B (en) 2021-10-31
CY1120516T1 (el) 2019-07-10
CA2985540C (en) 2021-08-24
HUE038541T2 (hu) 2018-10-29
MX2017014544A (es) 2018-09-26
KR20180021697A (ko) 2018-03-05
US20230226092A1 (en) 2023-07-20
US20210100825A1 (en) 2021-04-08
MY192081A (en) 2022-07-26
EP3197456B2 (en) 2023-10-11
EA201792509A1 (ru) 2018-05-31
RS57371B1 (sr) 2018-08-31
PL3197456T3 (pl) 2018-09-28
JP6761852B2 (ja) 2020-09-30
IL255591A (en) 2018-01-31
JP2018515618A (ja) 2018-06-14
SI3197456T1 (en) 2018-08-31
EP3415149A1 (en) 2018-12-19
BR112017024461B1 (pt) 2023-04-04
ES2668377T3 (es) 2018-05-17
TR201806642T4 (tr) 2018-06-21
PT3197456T (pt) 2018-05-22
WO2016181093A1 (en) 2016-11-17
CA2985540A1 (en) 2016-11-17
DK3197456T3 (en) 2018-06-06
EP3197456A1 (en) 2017-08-02
LT3197456T (lt) 2018-07-10
CN107835687A (zh) 2018-03-23
AU2015394135B2 (en) 2021-09-16
CN115837028A (zh) 2023-03-24
US20180289733A1 (en) 2018-10-11
PH12017502086A1 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
MX2020009154A (es) Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
PH12019501959A1 (en) Therapeutic rna
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2021006734A (es) Metodo para tratar el cancer.
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
GB2541571A (en) Pharmaceutical compositions
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
MX2018002344A (es) Metodo para tratar el cancer.
PH12018502491A1 (en) Cancer treatments
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2017003464A (es) Inhibidores de histona desmetilasa.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
IN2013MU03118A (es)
SG11201808253YA (en) Marker for predicting treatment response to anti-cancer agent in solid cancer patients
MX2017013669A (es) Composiciones para el tramiento del cancer.
MX2017012373A (es) Composiciones de astemizol y gefitinib para el tratamiento de cancer de pulmon.
PH12017501063A1 (en) Compounds for the treatment of cancer
GB2546703A (en) Compounds